Trials / Completed
CompletedNCT01961882
A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 60 Years
- Healthy volunteers
- Not accepted
Summary
To compare disease-free survival in patients 60 years or older with acute myeloid leukemia (AML) who are randomly assigned to receive either OCV-501 monotherapy or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OCV-501 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2017-11-16
- Completion
- 2017-11-16
- First posted
- 2013-10-14
- Last updated
- 2021-03-26
- Results posted
- 2021-03-26
Locations
14 sites across 3 countries: Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01961882. Inclusion in this directory is not an endorsement.